Curis (CRIS) closed at $0.65 on November 10, 2026, down 6.4% from the previous close, on volume of 1,122,764 shares (30-day average 8,148,583).
Data as of November 10, 2026.
Curis Faces Nasdaq Delisting Risk After Bid-Price Deficiency
TipRanks (Fri, 6-Nov 5:08 PM ET)
PRNewswire (Thu, 5-Nov 4:39 PM ET)
PRNewswire (Fri, 16-Oct 8:00 AM ET)
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
PRNewswire (Thu, 13-Aug 8:00 AM ET)
Market Chameleon (Wed, 22-Jul 4:12 AM ET)
CRIS Expands TakeAim CLL Study to Eleven Active Sites and Gets Green Light for Reverse Stock Split
Market Chameleon (Mon, 29-Jun 6:29 AM ET)
Market Chameleon (Thu, 8-Jan 6:56 AM ET)
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Curis trades on the NASDAQ stock market under the symbol CRIS.
As of November 11, 2026, CRIS stock price declined to $0.60 with 370,053 million shares trading.
CRIS has a beta of 4.01, meaning it tends to be more sensitive to market movements. CRIS has a correlation of 0.03 to the broad based SPY ETF.
CRIS has a market cap of $1.46 million. This is considered a Sub-Micro Cap stock.
Last quarter Curis reported $0 in Revenue and -$4.02 earnings per share. This fell short of revenue expectation by $-750,000 and exceeded earnings estimates by $1.29.
In the last 3 years, CRIS traded as high as $17.49 and as low as $.18.
The top ETF exchange traded funds that CRIS belongs to (by Net Assets): VXF.
CRIS has underperformed the market in the last year with a return of -54.2%, while the SPY ETF gained +12.6%. In the last 3 month period, CRIS fell short of the market, returning -83.6%, while SPY returned -1.5%. However, in the most recent 2 weeks CRIS has outperformed the stock market by returning +49.1%, while SPY returned -1.3%.
CRIS support price is $.56 and resistance is $.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRIS shares will trade within this expected range on the day.
